WebApr 13, 2024 · Licensed to Gilead a new development candidate, NX-0479/GS-6791, a targeted protein degrader of IRAK4, resulting in a $20 million payment Expanded therapeutic area potential of protein degradation ... WebOct 28, 2024 · Gilead's third quarter results topping expectations, and the biotech giant upped its guidance. Sales for the quarter was $7 billion, down slightly from $7.3 billion a year ago. But Piper Sandler and JP Morgan both upgrading the stock to overweight from neutral, while Truist upped its rating to buy and lifted its price target to 91 a share ...
Gilead Sciences, Inc. (GILD) Stock Price Today, News, Quotes, …
WebThe 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It’s calculated by averaging the closing stock price over the previous 50 trading days. Gilead Sciences, Inc. 50-day moving average is $82.06. Web17 hours ago · FOSTER CITY, Calif., April 13, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its first quarter 2024 financial results will be released on Thursday, April 27, 2024 after the ... filme little women
Gilead Sciences (GILD) Stock Sinks As Market Gains: What You ... - Yahoo
WebOct 28, 2024 · Yahoo Finance Live anchors discuss quarterly earnings for drug maker Gilead. Video transcript. JULIE HYMAN: One other company to discuss in our little earnings roundup here is Gilead, the drug maker. It is moving to the upside 10% after reporting better than expected profit from demand for its HIV and cancer drugs. WebDec 20, 2024 · December 20, 2024, 2:45 PM · 3 min read Gilead Sciences (GILD) closed the most recent trading day at $84.77, moving -1.91% from the previous trading session. … WebApr 29, 2024 · GILD stock has had a volatile ride since last year. It rallied from levels of under $65 in early January 2024 to $70 by March 23 2024, when broader markets made the bottom, given that Gilead’s ... group health mobile app